Pasithea (Charites)

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Retrieved on: 
Thursday, November 9, 2023
Survival, PNAS, IND, Stanford University, Patent, SOD1, KTTA, Clinical professor, Behavior, National academy, CNS, Natalizumab, Research, HIV disease progression rates, FN, Oregon Health & Science University, Disease, ALS, Multiple sclerosis, Integrin, Patient, Mayo Clinic, MS, SAN, Central nervous system, Pharmaceutical industry, Pasithea (Charites), Nature

SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that it has selected a lead therapeutic candidate for its PAS-003 program, a proprietary humanized monoclonal antibody (mAb) that targets α5β1 integrin, a protein found to be overexpressed in both human and mouse subjects with amyotrophic lateral sclerosis (ALS).

Key Points: 
  • Scientists at Pasithea have performed extensive mAb screening and characterization to enable selection of a lead therapeutic candidate with optimal properties for the treatment of ALS.
  • This work included further validation of α5β1 integrin as a target in both familial (SOD1) and sporadic (TDP-43) ALS mouse models with reproducible improvements on behavior and survival.
  • Extensive mechanism of action studies link disease model efficacy to effects on the migration and adhesion of immune cells.
  • Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea commented, “We have chosen the most optimal anti-α5β1 humanized mAb for the treatment of both sporadic and familial ALS.

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Retrieved on: 
Thursday, September 14, 2023
Central nervous system, PALO, Research, MEK, CNS, Suite, Share repurchase, KTTA, Hand, ALS, Alpha-5 beta-1, Pharmaceutical industry, Cryptocurrency, Security (finance), Telephone, Pasithea (Charites)

The tender offer expired at 5:00 p.m. on September 8, 2023 and was funded entirely through the Company’s cash on hand.

Key Points: 
  • The tender offer expired at 5:00 p.m. on September 8, 2023 and was funded entirely through the Company’s cash on hand.
  • Based on the final results, a total of 5,323,451 shares of common stock were validly tendered and not withdrawn.
  • Broadridge Corporate Issuer Solutions, LLC (“Broadridge”), the depositary for the tender offer, will promptly pay for all of the shares of common stock accepted for purchase in accordance with the terms and conditions of the tender offer.
  • For all questions relating to the tender offer, please contact: Secretary, Pasithea Therapeutics Corp., 1111 Lincoln Road, Suite 500, Miami Beach, Florida 33139, Email [email protected], Telephone (786) 977-3380 or Broadridge Corporate Issuer Solutions, LLC, Telephone (855) 793-5068, email [email protected].

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Retrieved on: 
Tuesday, August 1, 2023
Tissue, Myelocyte, National academy, PNAS, Central nervous system, Mayo Clinic, Macrophage, Stanford University, Oregon Health & Science University, PALO, Survival, Research, SOD1, CNS, Brain cell, KTTA, Gold, HIV disease progression rates, Patient, Ras Al Khaimah Medical and Health Sciences University, Integrin, Microglia, Clinical professor, ALS, Peripheral nervous system, Pharmaceutical industry, Vaccine, Pasithea (Charites)

PALO ALTO, Calif. and MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced a publication in the internationally renowned scientific peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS), related to its PAS-003 drug discovery program, that describes an increased expression of α5/β1 (α5) integrin on motor neurons in ALS human and mouse tissue, as well as the blockade of this integrin as a potential new approach to treat ALS patients.

Key Points: 
  • “This work began at Stanford University, where we have spent decades studying integrin related targets,” commented Pasithea's Chairman, Dr. Larry Steinman.
  • “It was especially gratifying to see the α5 antibody survival and behavioral benefits replicated at an independent CRO.
  • These results provide novel data on the role and spatial distribution of α5 integrin in ALS and provide efficacy data of anti-α5 integrin treatment in the SOD1G93A mouse model, the gold standard preclinical ALS model.
  • We believe this treatment may be used as a monotherapy or in combination with existing standard of care in both sporadic and genetic type of ALS.

Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004

Retrieved on: 
Thursday, June 29, 2023
GMP, PK, Wuxi, Partnership, Central nervous system, PALO, CMC, API, MEK inhibitor, Research, Chemistry, KTTA, Investigational New Drug, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry, Fine chemical, Pasithea (Charites)

GMP-compliant manufacturing of API was the final step needed to support the Investigational New Drug (“IND”) application that the Company expects to file with the U.S. Food and Drug Administration (“FDA”) in the second half of 2023.

Key Points: 
  • GMP-compliant manufacturing of API was the final step needed to support the Investigational New Drug (“IND”) application that the Company expects to file with the U.S. Food and Drug Administration (“FDA”) in the second half of 2023.
  • The Company intends to utilize this supply of PAS-004 for its upcoming Phase I clinical trial.
  • Dr. Tiago Reis Marques, Pasithea’s Chief Executive Officer, commented “We are pleased to have reached this milestone efficiently and on time.
  • We are grateful to WuXi STA for its expertise throughout the process, development and manufacturing of the API.

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Retrieved on: 
Tuesday, June 6, 2023
KTTA, Central nervous system, Research, CNS, PALO, Management, Financial adviser, Pasithea (Charites)

PALO ALTO, Calif. and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, confirmed it has received an unsolicited proposal from Lucy Scientific Discovery Inc. (NASDAQ: LSDI) (“Lucy”) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.

Key Points: 
  • PALO ALTO, Calif. and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, confirmed it has received an unsolicited proposal from Lucy Scientific Discovery Inc. (NASDAQ: LSDI) (“Lucy”) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.
  • Pasithea’s Board of Directors and management team regularly review opportunities to generate shareholder value and are committed to acting in the best interests of all shareholders.
  • Consistent with its fiduciary duties, Pasithea’s Board of Directors, in consultation with its independent financial and legal advisors, will carefully review and evaluate the proposal from Lucy to determine the course of action that it believes is in the best interests of the Company and its shareholders.
  • Pasithea shareholders do not need to take any action at this time.

Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp.

Retrieved on: 
Monday, June 5, 2023
Biotechnology, KTTA, Hand, Cryptocurrency, Pasithea (Charites)

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “the Company”) (NASDAQ: LSDI), a licensed producer of compounds for medicinal products, today announced that it sent a proposal to Pasithea Therapeutics Corp. (“Pasithea”) (NASDAQ: KTTA), a biotechnology firm focused on innovative medical solutions, to acquire each share of its common stock.

Key Points: 
  • VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “the Company”) (NASDAQ: LSDI), a licensed producer of compounds for medicinal products, today announced that it sent a proposal to Pasithea Therapeutics Corp. (“Pasithea”) (NASDAQ: KTTA), a biotechnology firm focused on innovative medical solutions, to acquire each share of its common stock.
  • Under the terms of the offer, Lucy proposes to pay $0.60 in cash, and $0.25 cents in Lucy stock (NASDAQ: LSDI) for every share of Pasithea common stock.
  • Given that Pasithea’s stock closed at $0.35 per share on June 1, 2023, the Proposal of $0.85 per share equates to 142% premium to Pasithea’s share price.
  • In the event that the proposal is not endorsed by Pasithea's Board of Directors, Lucy is prepared to present it directly to the Pasithea shareholders.

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

Retrieved on: 
Monday, December 12, 2022
Shareholder, Concord, Psychopharmacology, Multiple sclerosis, Psychiatry, LP, Noonan syndrome, CNS, Amyotrophy, Security (finance), ALS, Agreement, Biotechnology, Amyotrophic lateral sclerosis, Central nervous system, MIAMI, Neuroscience, Prejudice, KTTA, Research, Cooperation, Therapy, Patient, Pharmaceutical industry, Pasithea (Charites)

Pursuant to the Agreement, the Camac Group has agreed to a three-year standstill provision and the parties have agreed to dismiss with prejudice the pending Delaware litigation against the Company and the Board filed by the Camac Group.

Key Points: 
  • Pursuant to the Agreement, the Camac Group has agreed to a three-year standstill provision and the parties have agreed to dismiss with prejudice the pending Delaware litigation against the Company and the Board filed by the Camac Group.
  • Pasithea will also reimburse certain fees and expenses of the Camac Group.
  • We are excited about Pasithea’s potential to advance our therapies and achieve value-creating milestones.”
    Eric Shahinian of the Camac Group further commented, “We are pleased to have reached this settlement with Pasithea.
  • Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders.

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Retrieved on: 
Wednesday, December 7, 2022
Banking, Professional Services, Finance, Partner, KTTA, Special, CARD, Internet, Telephone, Holding company, Pasithea (Charites), Shareholder

By removing the Companys current directors, we believe Pasithea will finally be positioned to enhance its corporate governance, improve capital allocation and unlock significant value for all stockholders.

Key Points: 
  • By removing the Companys current directors, we believe Pasithea will finally be positioned to enhance its corporate governance, improve capital allocation and unlock significant value for all stockholders.
  • Protect the value of your investment TODAY and vote FOR all matters on the WHITE proxy card by telephone, over the Internet, or by signing, dating and returning your WHITE proxy card in the postage-paid envelope provided.
  • VOTE THE WHITE PROXY CARD TODAY.
  • If you have any questions on how to vote your shares on the WHITE proxy card, please contact InvestorCom LLC by email at [email protected] or by telephone at 203-972-9300.

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Retrieved on: 
Tuesday, November 22, 2022
Professional Services, Finance, Partner, Telephone, Pasithea (Charites), KTTA, Special, Holding company, Shareholder

We are deeply disappointed that Pasithea has scheduled the Special Meeting to occur with just a few days of notice and over a holiday period.

Key Points: 
  • We are deeply disappointed that Pasithea has scheduled the Special Meeting to occur with just a few days of notice and over a holiday period.
  • This is a stunning disregard for stockholder rights, and it is another in a long line of actionsincluding multiple dilutive acquisitionstaken by the incumbent Board that are calculated to disenfranchise stockholders.
  • We strongly believe that it is time for stockholders to take back their Company and vote to remove all of Pasitheas sitting directors.
  • If you have any questions on how to vote your shares on the WHITE proxy card, please contact InvestorCom LLC by email at [email protected] or by telephone at 203-972-9300.

EQS-News: A New BioTech Research Race Is Focused On Improving Life For MS Patients

Retrieved on: 
Friday, October 28, 2022
MS, Multiple sclerosis, Lists of diseases, Virus, CNS, Immune tolerance, AstraZeneca, Central nervous system, NASDAQ, KTTA, Diagnosis, Brain, Risk, Chinese, Ketamine, Neurodegeneration, Vaccine, BioNTech, JNJ, National, Chinese University of Hong Kong, Patient, Technology, Amyotrophic lateral sclerosis, Johnson & Johnson, BNTX, Spinal cord, Immune system, Research, COVID-19, Amyotrophy, Modified, Attention, Psychiatry, MRNA, Therapy, Biomarker, Psychopharmacology, RNA transfection, ALS, NYSE, Health status of Asian Americans, Animal, Advertising, Pharmaceutical industry, Medical device, MVA, Moderna, Pasithea (Charites), Science

As companies launch new products and research, government initiatives are projected to improve the accessibility of care and treatment.

Key Points: 
  • As companies launch new products and research, government initiatives are projected to improve the accessibility of care and treatment.
  • The rising MS numbers are believed to be the primary catalyst in market expansion.
  • Some are finding new research showing that an mRNA vaccine might also work in multiple sclerosis (MS).
  • Another recent article in Science showed published research that scientists have discovered about the risk of an individual contracting MS.